Award Banner
Award Banner

Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation

Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation BioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – empowers scientists to accelerate discovery of new vaccines and biologics GlobeNewswire September 19, 2022

SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the BioXp™ 9600 system, a next-generation high throughput platform designed to revolutionize synthetic biology workflows. The latest instrument further accelerates the design-build-test process of research and discovery by building biology overnight and at the push of a button.

The fully automated BioXp™ system enables scientists to overcome process limitations created by the turnaround time, cost, or complexity of alternative means of building or acquiring DNA and mRNA. The BioXp™ system provides over-night, automated synthesis of genes, clones, DNA libraries, and mRNA, enabling users to more tightly integrate design and build cycles, driving greater productivity and reducing time to answer.

“Codex DNA is committed to empowering and inspiring scientists to advance their discovery of life-changing vaccines and biologics. We believe the BioXp™ 9600 system, the third release on our versatile and powerful BioXp platform, can enable scientists to overcome inefficiencies in their workflows which limit their discovery. Demonstrating our commitment, we accelerated development of this system, releasing one quarter ahead of schedule,” said Todd R. Nelson, PhD, CEO of Codex DNA.

“The versatility of the platform enables us to release additional capabilities intended to optimize discovery workflows. Beginning in Q1 of 2023 we will release additional BioXp kits that enable scientists to begin the cloning, amplification, and mRNA synthesis process from the customers own linear DNA or plasmid DNA. We believe providing scientists the flexibility to begin with their sequence, linear DNA, or plasmid DNA, will further expand the utility, speed, and impact of the system,” said Todd R. Nelson, PhD, CEO of Codex DNA.

About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit

Codex DNA, the Codex DNA logo, Gibson Assembly, BioXp, and RapidAMP are trademarks of Codex DNA Inc.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Codex DNA’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Codex DNA’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in Codex DNA’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Codex DNA subsequently files with the SEC from time to time. Except to the extent required by law, Codex DNA undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Charlie Schmidt
Sr. Director of Marketing

Primary Logo

This website is best viewed using the latest versions of web browsers.